Malaria DNA Vaccine: Phase I started

VaxOnco began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 39 healthy volunteers to evaluate 0.25, 1 and 4 mg EP1300 administered on days 0, 28 and 56 using TriGrid elect...